Medical Center Hera EOOD
- Address
- lock Available on a paid plan
Medical Center Hera EOOD - Comprehensive Clinical Research Center
Medical Center Hera EOOD is a multidisciplinary clinical research facility with extensive experience across diverse therapeutic areas. The center demonstrates particular strength in conducting complex neuropsychiatric, immunological, and cardiovascular studies, partnering with leading pharmaceutical companies to advance treatment options for patients with serious medical conditions.
- Neuropsychiatric disorders including schizophrenia, Alzheimer's disease psychosis, major depressive disorder, and generalized anxiety disorder
- Dermatological and immunological conditions such as atopic dermatitis, hidradenitis suppurativa, psoriasis, and chronic urticaria
- Cardiovascular and metabolic diseases including heart failure, hypertension, hypertriglyceridemia, and atherosclerotic cardiovascular disease
- Respiratory conditions including severe asthma, COPD, RSV infection, and allergic rhinoconjunctivitis
The center specializes in both early-phase and late-stage clinical trials, including long-term extension studies that evaluate sustained safety and efficacy of investigational therapies. Medical Center Hera EOOD has demonstrated capability in managing biosimilar studies, Phase 3 pivotal trials, and complex dose-finding investigations. Their research portfolio encompasses novel therapeutic approaches including monoclonal antibodies, JAK inhibitors, muscarinic receptor agonists, and innovative RNA-based therapies, reflecting their commitment to advancing precision medicine across multiple disease states.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 14 therapeutic areas and 15 of 163 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 162 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 37 by active trials.
- 1Intra-Cellular Therapies Inc.5active
lock +36 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +29 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medical Center Hera EOOD
lock Showing 1 of 124 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-week, randomised, double blind, multicentre, 2-arm parallel group trial assessing the efficacy and safety of CHF6001 (total daily dose 3200 μg) Dry Powder Inhaler (DPI) add-on to maintenance medium or high dose inhaled corticosteroid in combination with long-acting ß2-agonists in subjects with uncontrolled asthma | Chiesi Farmaceutici S.p.A. | Phase II | Not Recruiting | Nov 2023 | Dec 2025 |
IMP list
lock Showing 1 of 163 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Glycopyrronium Bromide | 4 | Unknown | 2022-08-29 | 2026-04-13 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.